Arcus Biosciences (RCUS) CEO Terry Rosen donates 35,000 shares in Form 4

Rhea-AI Filing Summary

Arcus Biosciences Chief Executive Officer and director Terry J. Rosen reported a charitable gift of company stock. On 01/08/2026, Rosen donated 35,000 shares of Arcus Biosciences, Inc. common stock, coded as a charitable gift transaction. The shares were transferred at a reported price of $0 per share, consistent with a non-cash donation. After this gift, Rosen beneficially owned 2,157,409 shares of common stock, which the disclosure notes includes the unvested portion of his restricted stock unit grants. This filing updates the market on Rosen’s current direct equity stake in the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROSEN TERRY J

(Last) (First) (Middle)

C/O ARCUS BIOSCIENCES, INC.

3928 POINT EDEN WAY

(Street)

HAYWARD CA 94545

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arcus Biosciences, Inc. [ RCUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/08/2026		G(1)		35,000	D	$0	2,157,409(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a charitable gift by the reporting person.

2. Includes the unvested portion of the reporting person's RSU grants.

Remarks:

	/s/ Carolyn Tang, Attorney-in-Fact	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Arcus Biosciences (RCUS) report for Terry J. Rosen?

Arcus Biosciences reported that Chief Executive Officer and director Terry J. Rosen made a charitable gift of 35,000 shares of the company’s common stock on 01/08/2026, recorded under transaction code G.

How many Arcus Biosciences (RCUS) shares does Terry J. Rosen own after this Form 4 transaction?

Following the reported charitable gift, Terry J. Rosen beneficially owned 2,157,409 shares of Arcus Biosciences common stock. This figure includes the unvested portion of his restricted stock unit (RSU) grants.

What does transaction code G mean in the Arcus Biosciences (RCUS) Form 4 filing?

In this Form 4, transaction code G is explained in the footnotes as representing a charitable gift by the reporting person, indicating the shares were donated rather than sold on the market.

Was the Arcus Biosciences (RCUS) CEO’s charitable gift a cash or non-cash transaction?

The Form 4 shows the 35,000 donated shares at a reported price of $0 per share, indicating a non-cash charitable transfer of Arcus Biosciences common stock.

Does Terry J. Rosen’s reported ownership in Arcus Biosciences (RCUS) include unvested RSUs?

Yes. A footnote specifies that the 2,157,409 shares Rosen beneficially owns include the unvested portion of his RSU grants.

What is Terry J. Rosen’s role at Arcus Biosciences (RCUS) as disclosed in the Form 4?

The Form 4 identifies Terry J. Rosen as both a director and an officer of Arcus Biosciences, with the officer title of Chief Executive Officer.